tiprankstipranks
Alzamend Neuro gets ‘Study May Proceed’ letter for AL001 from FDA to treat MLS
PremiumThe FlyAlzamend Neuro gets ‘Study May Proceed’ letter for AL001 from FDA to treat MLS
5M ago
Alzamend Neuro regains compliance with Nasdaq
PremiumThe Fly
Alzamend Neuro regains compliance with Nasdaq
5M ago
Alzamend Neuro submits AL001-PTSD01 IND application to FDA
PremiumThe Fly
Alzamend Neuro submits AL001-PTSD01 IND application to FDA
5M ago
Alzamend Neuro submits AL001-BD01 IND application to FDA
PremiumThe FlyAlzamend Neuro submits AL001-BD01 IND application to FDA
8M ago
Alzamend Neuro files $25M mixed securities shelf
PremiumThe Fly
Alzamend Neuro files $25M mixed securities shelf
9M ago
Alzamend Neuro identifies MTD for development of AL001
PremiumThe Fly
Alzamend Neuro identifies MTD for development of AL001
10M ago
Alzamend Neuro receives Study May Proceed letter from FDA for Alzheimer’s study
PremiumThe FlyAlzamend Neuro receives Study May Proceed letter from FDA for Alzheimer’s study
1y ago
Alzamend Neuro announces completion of clinical portion of Phase IIA MAD trial
PremiumThe Fly
Alzamend Neuro announces completion of clinical portion of Phase IIA MAD trial
1y ago
Alzamend Neuro teams with UofM on ALZN002 trial for Alzheimer’s
PremiumThe Fly
Alzamend Neuro teams with UofM on ALZN002 trial for Alzheimer’s
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100